Pharma Pulse 10/15/24: Understanding Acceptability of eConsent, Advances in Oncology Care & more

Understanding Acceptability of eConsent from a Global, Ethical, and Industry Perspective

To date, there is limited insight into the perspectives on eConsent in clinical trials of Independent Ethics Committees/Institutional Review Boards, collectively referred to as Ethics Committees (ECs) in this article, as well as into the opportunities and barriers faced by sponsors (commercial, non-commercial) and vendors (technology companies, CROs). The European Forum for Good Clinical Practice (EFGCP) eConsent initiative, comprised of over 50 companies, has conducted two surveys to gain a comprehensive understanding into behind-the-scenes perspectives of ECs and sponsors/vendors. This article represents the key findings of both surveys and detailed results can be accessed through the supplemental information section.

Advances in Oncology Care: Emerging Therapies, AI Integration, and Access to Investigational Drugs

The authors of these peer -reviewed papers collectively emphasize the evolving landscape of oncology treatment.

This AI Pioneer Thinks AI Is Dumber Than a Cat

Yann LeCun, an NYU professor and senior researcher at Meta Platforms, says warnings about the technology’s existential peril are ‘complete B.S.’

Humana Partnership With Volunteers of America Expands Access to Integrated Healthcare for Historically Unsupported Communities

Leading health and well-being company Humana Inc., continues to focus on advancing health equity with significant commitments to local affiliates of Volunteers of America (VOA).

uMed on LinkedIn

The Future of Obesity Pharmacology & Bridging Evidence Gaps with uMed’s CEO & Founder Dr Matt Wilson🚀

In this article with Pharmaceutical Executive, Matt discusses the need for robust evidence that goes beyond just routinely collected data and that accurately reflects the diverse patient populations affected by obesity.

By leveraging advanced data collection methods, including patient-reported outcomes and digital health tools, the healthcare industry can build stronger evidence, enhancing the personalization and effectiveness of obesity treatments for broader populations. This shift promises to bridge gaps in clinical research and support better decision-making across the pharmaceutical and healthcare sectors.

Read the full article 👉https://lnkd.in/ezhyVCJf

To find out how uMed's AccessCMD Cohort is enabling the generation of richer more comprehensive evidence for #obesity and #cardiometabolic research, get in touch at hello@umed.io or visit: https://lnkd.in/exmaAk8i

#obesityresearch #cardiometabolicresearch #diabetes #digitalresearchtools

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs